|Articles|February 15, 2007
Visiogen continues study of dual-optic IOL
Irvine, CA-Visiogen Inc. says it has received FDA approval to expand its phase III U.S. clinical trial for its dual-optic accommodating IOL (Synchrony).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
PainReform launches development plan for OcuRing-K, readies phase 2 trial
3
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
4
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
5











































.png)


